Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage
NCT ID: NCT02075307
Last Updated: 2020-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
7 participants
INTERVENTIONAL
2014-01-31
2017-04-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blueberry Powder
The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
Blueberry Powder
Placebo Powder
The placebo group will receive placebo powder in the same amounts for the same duration.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blueberry Powder
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI \> 30;
3. Blood pressure \<140/90 mmHg without antihypertensive medicines or with a stable dose of antihypertensive medicines (no change in last 3 months).;
4. Insulin resistance (HOMA/IR) \> 2.0;
5. Willing to restrict intake of high polyphenol-containing foods during the trial period;
6. Willing to forego intake of nutritional supplements other than a multivitamin;
7. Willing to maintain their current daily level of exercise throughout the study.
Exclusion Criteria
2. Medications known to affect glucose metabolism;
3. Weight loss pharmacotherapy;
4. Lipid-lowering medication;
5. Untreated thyroid or chronic liver, renal, or cardiovascular disease;
6. Smoking;
7. Pregnancy- a negative urine pregnancy test will be documented for any women participants of childbearing age prior to enrollment.
8. History of allergic reactions to blueberries.
9. Any pathological condition known to alter white blood cell count over the previous 6 months;
10. Exposure to drugs known to cause mutations or radiation within the previous 6 months;
11. Alcohol consumption greater than 2 drinks/d for males and 1 drink/d for females.
30 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
U.S. Highbush Blueberry Council
OTHER
USDA Agricultural Research Station in Albany, CA
UNKNOWN
UCSF Benioff Children's Hospital Oakland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruce Ames, PhD
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital & Research Center at Oakland
Ashutosh Lal, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital & Research Center at Oakland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hospital & Research Center Oakland
Oakland, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-033
Identifier Type: -
Identifier Source: org_study_id